Edesa Biotech Inc Dossier - Source-backed chat

Edesa Biotech Inc

EDSANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.06

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.01Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $38.7M

Enterprise Value $28.4M

Shares Outstanding 9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing host-directed therapeutics for inflammatory and immune-related diseases. The company's lead candidate, paridiprubart (EB05), has demonstrated statistically significant mortality reductions in a Phase 3 study of hospitalized ARDS patients. Additionally, Edesa is preparing to initiate a Phase 2 study for EB06 in vitiligo. While the company faces typical clinical-stage risks, including cash burn and dilution, its robust clinical data and government funding support a positive outlook.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$16.33

High · most bullish analyst$21.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$5.0015%

Clinical trials face delays, regulatory feedback for paridiprubart is unfavorable, or the company is forced to raise capital under highly dilutive terms, depressing the stock price.

Base CaseCentral scenario

$19.0060%

Edesa successfully initiates the Phase 2 vitiligo trial for EB06 and continues constructive regulatory discussions for paridiprubart, maintaining steady clinical progress with manageable dilution.

Bull CaseUpside scenario

$19.0025%

Paridiprubart receives expedited regulatory approval or a major government stockpiling contract for ARDS, while EB06 demonstrates strong efficacy in the Phase 2 vitiligo trial, driving significant upward valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase 3 clinical data for paridiprubart (EB05) showing mortality benefit in ARDS patients.
Diverse pipeline with late-stage assets in both respiratory and medical dermatology indications.
Supportive non-dilutive funding from the Canadian government's Strategic Innovation Fund.
Active insider participation, including a recent $0.8 million private share purchase by the CEO.

Key Investment Risks

Clinical-stage risk with no approved products or recurring revenue streams.
Ongoing cash burn and potential need for dilutive capital raises.
Regulatory hurdles and potential delays in clinical trial initiation or approval.

Thesis Invalidation Triggers

Failure to obtain regulatory approval to initiate the Phase 2 vitiligo study for EB06.
Negative feedback from regulatory authorities regarding the paridiprubart clinical data package.
Severe capital constraints leading to a halt in clinical development programs.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.